Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.53 |
| ▸ | ITGAL | P20701 | 7/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | ECE1 | P42892 | 3/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516957 | 0.86 | ITGB2 (0.63) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL28516953 | 0.86 | ITGB2 (0.63) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL837864 | 0.85 | TNF (0.68) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL29530632 | 0.85 | TNF (0.71) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL836657 | 0.85 | TNF (0.68) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL28880060 | 0.84 | ACE (0.56) | ITGB2ICAM1ITGALACETACR1 | |
| SCHEMBL28880058 | 0.84 | ACE (0.56) | ITGB2ICAM1ITGALACETACR1 | |
| SCHEMBL8251031 | 0.81 | NMBR (0.56) | ITGB2ICAM1ITGALACEECE1 | |
| Acetyltryptophan SCHEMBL702442 | 0.80 | ALOX15 (0.79) | ITGB2ICAM1ITGALALOX15ACE | |
| Acetyltryptophan SCHEMBL57141 | 0.80 | ALOX15 (0.79) | ITGB2ICAM1ITGALALOX15ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538129-B2 | modeled after unique toxins extracted from marine invertebrate Diazona angulata; antimitotic, antiproliferative and anticarcinogenic agents; to treat in particular Taxol (TM) -resistant cancers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-05-26 | — | — | US | disclosed |
| CN-101340907-A | Indolin A analogues | UNIV TEXAS (US) | 2009-01-07 | — | — | CN | disclosed |
| US-20070149583-A1 | Diazonamide a analog | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149583-A1 | Diazonamide a analog | GLS, PKD1, PKD2 | TNF 3921/4885ITGB2 4582/4885ICAM1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.